Lack of effect of azelastine and ketoconazole coadministration on electrocardiographic parameters in healthy volunteers

Journal of Clinical Pharmacology

Volumn 37, Issue 11, 1997, Pages 1065-1072

  Morganroth, J ^a,b   Lyness, W H ^a   Perhach, J L ^b   Mather, G G ^b   Harr, J E ^c   Trager, W F ^c   Levy, R H ^c   Rosenberg, A ^c  

^a Premier Research   (United States)

^b Wallace Laboratories   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELASTINE; CYTOCHROME P450; KETOCONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; ELECTROCARDIOGRAPHY; HEMODYNAMIC PARAMETERS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIVER MICROSOME; MALE; PR INTERVAL; QRS COMPLEX; RR INTERVAL;

EID: 0030832936     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04289.x     Document Type: Article

References (15)

1. Perhach JL, Chand N, Diamantis VV, Sofia RD, Rosenberg A: Azelastine: a novel oral antiasthma compound with several modes of action. In Kay AB (ed). Allergy and Asthma. New Trends and Approaches to Therapy. Oxford, London: Blackwell Scientific Publications, 1989:230-248.
2. Szelenyi L: Pharmacological profile of azelastine. Drugs Today 1989:25:3-8.
3. Hazama H, Nakajima T, Hisada T, Hamada E, Omata M, Kurachi Y: Effects of azelastine on membrane currents in trachéal smooth muscle cells isolated from the guinea-pig. Eur JPharmacol 1994;259:143-150.
4. Woosley RL, Chen Y, Frieman JP, Gillis RA: Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993:269:1532-1536.
5. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR: Terfenadine-ketoconazole interaction: pharmacokinetic and electrographic consequences. JAMA, 1993:269:1513-1518.
6. Honig PK, Woosley RL, Zamani K, Conner DP, Candela LR: Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-238.
7. Honig PK, Wortham DC, Hull R, Zamani K, Smith JE, Cantilena LR: Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. / Clin Pharmacol 1993:33:1201-1206.
8. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P: Torsades de pointes after terfenadine-interaction. BAJJ1993;306:186.
9. Simons, FE, Kesselman MS, Giddins NG, Pelech AN, Simons KJ: Astemizoleinduced torsades de pointes (letter). Lancet 1988;2:624.
10. Browne KF, Prystowsky E, Heger JJ, Chilson DA, Zipes DP: Prolongation of the Q-T interval in man during sleep. AmJCardiol 1983:52:55-59.
11. Pudda PE, Jouve R, Mariotti S, Giampaoli S, Lanti M, Realo A, Menotti A: Evaluation of 10 QT prediction formulas in 881 middle-aged men from seven countries study: emphasis on the cubic Root Fridericia's equation. / Electrocardiol 1988;21:219-229.
12. Pivonka J, Segalman FH, Hartman C, Segal WE, Kucharczyk N, Sofia RD: Determination of azelastine and desmethylazelastine in human plasma by high performance liquid chromatography. J Chromatogr 1987;420:89-98.
13. Mather GG, Levy RH: Pharmacokinetics of polypharmacy: prediction of drug interactions. Epilepsy Research (in press).
14. Spector S, Rohr A, Rachelefsky G, Katz R, Siegel S, Perhach JL, Newton J: Pharmacodynamic evaluation of azelastine in asthmatics. J Allergy Clin Immunol 1986; 77:249.
15. Sale ME, Lyness WH, Perhach JL, \Voosley R, Rosenberg A: Lack of effect of coadministration of erythromycin with azelastine on pharmacokinetic or EGG parameters. Ann Allergy Asthma Immunol 1996;76:91.